CN114983673B - Injection device for ophthalmic injection and application thereof - Google Patents
Injection device for ophthalmic injection and application thereof Download PDFInfo
- Publication number
- CN114983673B CN114983673B CN202210851407.XA CN202210851407A CN114983673B CN 114983673 B CN114983673 B CN 114983673B CN 202210851407 A CN202210851407 A CN 202210851407A CN 114983673 B CN114983673 B CN 114983673B
- Authority
- CN
- China
- Prior art keywords
- needle
- stopper
- injection device
- injection
- length
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002347 injection Methods 0.000 title claims abstract description 88
- 239000007924 injection Substances 0.000 title claims abstract description 88
- 208000024304 Choroidal Effusions Diseases 0.000 claims abstract description 17
- 239000007788 liquid Substances 0.000 abstract description 9
- 210000003161 choroid Anatomy 0.000 abstract description 8
- 230000000149 penetrating effect Effects 0.000 abstract description 7
- 238000000034 method Methods 0.000 description 13
- 210000005252 bulbus oculi Anatomy 0.000 description 10
- 239000003814 drug Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- -1 cells Substances 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 210000003786 sclera Anatomy 0.000 description 4
- 239000004743 Polypropylene Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000001508 eye Anatomy 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000002445 nipple Anatomy 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000001747 pupil Anatomy 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 201000003533 Leber congenital amaurosis Diseases 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010063942 Vitreous loss Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012780 transparent material Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/00736—Instruments for removal of intra-ocular material or intra-ocular injection, e.g. cataract instruments
Abstract
The application discloses an injection device for ophthalmic injection, which comprises an injector and a limiter, wherein a needle head of the injector comprises a pintle and a hollow needle head main body, a thin part is arranged at the far end of the hollow needle head main body, the length of the thin part is 0.6-2mm, and the outer diameter of the thin part is 0.25-0.35mm; the stopper comprises a base and a handheld part, wherein a needle channel in which the hollow needle head main body can be embedded is arranged on one side surface of the handheld part, and an included angle of 20-70 degrees is formed between the needle channel and the height direction of the stopper. The injection device is used for injecting the suprachoroidal space, the injection position is accurate, the suprachoroidal space can be accurately determined, the needle point penetrates into the suprachoroidal space at a certain angle, the risk of the liquid penetrating through the choroid is reduced, the operation is simple, and the dependence on doctor experience is greatly reduced.
Description
Technical Field
The application belongs to the field of ophthalmic surgery devices, and particularly relates to an injection device for ophthalmic injection and application thereof.
Background
Successful treatment of ocular diseases depends not only on the development of novel drugs, but also on effective methods of administration to increase the concentration of the drug in the target tissue to achieve the desired effect. Researchers have been actively exploring new ways to deliver drugs, cells, implants and other fluids to treat various eye conditions and reduce the blinding rate. Many successful or promising clinical trials and experimental studies have focused on testing the pharmaceutical technology using three intraocular injection techniques: intravitreal (IVT), subretinal (SR), and Suprachoroidal (SC) injections, with IVT injections being the most successful. However, the intravitreal injection method cannot sufficiently transduce the target gene to the photoreceptor due to the Inner Limiting Membrane (ILM) barrier. Although the transfection efficiency can be improved by removing the inner limiting membrane by using a surgical method, the corresponding surgical risk is increased, thereby limiting the application of the method in the field of gene therapy. SR injection is widely used in gene therapy and cell transplantation for hereditary retinal diseases, such as Leber congenital amaurosis, retinitis Pigmentosa (RP), stargardt's macular degeneration. However, as the most invasive method of intraocular injection is the potential surgical risk such as vitreous loss, retinal detachment and hemorrhage all discourage SR multi-site repeat injections.
As an emerging field of importance in ophthalmology, suprachoroidal injection has gained increasing attention in recent years in its minimally invasive and repeatable characteristics. The micro-needle is less invasive and more effective than conventional needles in placing the desired materials of different shapes and sizes into the suprachoroidal space, reducing damage to the retinal layer. The key to SC injection is the need to place the drug or gene directly in the potential space between the sub-sclera and the suprachoroid without puncturing the choroidal vessels or disrupting any underlying tissue structure. The ideal length should therefore be comparable to the scleral thickness, and in view of this requirement the needle length has been reduced to the size of a micron, i.e. less than 1mm. SC-dedicated syringes are not as diverse as IVT needles, and the products for clinical use are very few and imperfect.
In the prior art, in the existing SC syringe at home and abroad, visitisti changes a hypodermic needle of normal length into a suprachoroidal needle by controlling the length of a needle tip in an adapter. The adapter is combined with the needle guide for injection, and the adapter can keep the eyelid open and stabilize the eyeball. SCSMicroinjector TM Is a special syringe for suprachoroidal injection of triamcinolone acetonide suspension on the market. Both the two special injectors are in a needle inserting mode perpendicular to the sclera, and although the length of the needle head is adjustable, the injection accuracy of the suprachoroidal space cannot be completely ensured in the practical application process due to the fact that the sclera thickness has individual difference and difference of different health states. The suprachoroidal delivery system of the ETHICONENDO-SURGERY, INC. Design includes a body, a cannula, a hollow needle, and an actuation assembly. The structure is relatively complex, the requirement on the proficiency of the operation technology is high, and the clinical popularization and application are not facilitated. The tissue-targeting smart syringe (I2T 2) designed by harvard medical college is similar to a conventional syringe in that when pressure is applied to the plunger, the needle tip can be inserted into the harder outer tissue independently of the barrel movement by the joint component design, and when the needle reaches the soft target tissue, the mechanical feedback effect stops the needle from advancing and the plunger will push the drug out of the tip. Compared with the above syringes, the design is simple and convenient, the precision is improved, but the requirements on the needle inserting speed and the stability of an injector in the actual operation are very high, and the requirements are not favorable for clinicians with insufficient experience to master, so that the popularization and the application are difficult.
Therefore, how to change the current situation that the suprachoroidal space injector in the prior art is complicated in structure, difficult to operate and incapable of ensuring accuracy becomes a problem to be solved urgently by those skilled in the art.
Disclosure of Invention
The purpose of the present application is to provide an injection device for ophthalmic injection and use thereof.
In order to solve the technical problems, the following technical scheme is provided:
the first aspect of the application provides an injection device for ophthalmic injection, which comprises an injector and a stopper, wherein the injector comprises a syringe and a needle which are detachably connected, the needle comprises a pintle and a hollow needle body, and the pintle is used for being connected with the syringe; the far end of the hollow needle head main body is provided with a thin part, the length of the thin part is 0.6-2mm, the outer diameter of the thin part is 0.25-0.35mm, and the far end of the thin part is provided with a needle point;
the stopper comprises a base and a handheld part arranged above the base, a needle channel capable of embedding the hollow needle head main body is arranged on one side surface of the handheld part of the stopper, and an included angle of 20-70 degrees, preferably 30-45 degrees, is formed between the needle channel and the axis of the stopper in the height direction; the needle channel penetrates through the base;
the length of the needle channel is less than or equal to that of the hollow needle head main body, and when the hollow needle head main body is embedded into the needle channel, the thin part can be completely exposed from the bottom surface of the base.
A second aspect of the present application provides a needle for an ophthalmic injector comprising a pintle for connection to the barrel and a hollow needle body; the hollow needle comprises a hollow needle body and is characterized in that the far end of the hollow needle body is provided with a thin part, the length of the thin part is 0.6-2mm, the outer diameter of the thin part is 0.25-0.35mm, and the far end of the thin part is provided with a needle point.
In a third aspect, the present application provides a barrel for an ophthalmic injector having a length to diameter ratio of 20 to 60; preferably, the inner diameter of the needle cylinder is 1-3mm; preferably, the range of the needle cylinder is 100-500 muL; preferably 100-200. Mu.L.
A fourth aspect of the present application provides an ophthalmic injector comprising a needle as provided in the second aspect of the present application and/or a barrel as provided in the third aspect of the present application.
The fifth aspect of the application provides a stopper for ophthalmic injection, which comprises a base and a handheld part arranged above the base, wherein the stopper is provided with a needle channel capable of embedding a needle of a syringe on one side surface of the handheld part, and the needle channel and an axis of the stopper in the height direction form an included angle of 20-70 degrees, preferably 30-45 degrees; the needle channel penetrates through the base.
A sixth aspect of the present application provides a method of controlling the direction of egress of a syringe needle using an injection device of the first aspect of the present application, comprising:
injecting the injection into a needle cylinder, and connecting the needle cylinder with a needle head;
placing a hollow needle head main body of a needle head of the syringe in a needle channel of the stopper, wherein the open end of the needle point is upward;
the thin part of the syringe needle extends out of the bottom surface of the limiter along the needle path direction, and pushes the piston in the syringe to push out the injection in the direction which forms an included angle of 0-60 degrees with the bottom surface of the limiter.
A seventh aspect of the present application provides an injection device for ophthalmic injection of the first aspect of the present application, a needle of an ophthalmic injector of the second aspect of the present application, a barrel of an ophthalmic injector of the third aspect of the present application or a use of an ophthalmic injector of the fourth aspect of the present application for ophthalmic injection; preferably, the ophthalmic injection is suprachoroidal injection.
An eighth aspect of the present application provides a method for suprachoroidal space injection using the ophthalmic injection device of the first aspect of the present application, comprising:
injecting the injection into a needle cylinder, and connecting the needle cylinder with a needle head;
placing the stopper on a part to be injected, wherein the bottom end of the needle channel is aligned with a point to be injected;
placing a hollow needle head main body of a needle head of the syringe in a needle channel of the stopper, wherein the open end of the needle point is upward;
stretching the thin part of the injector out of the bottom surface of the limiter along the needle path direction, and penetrating the thin part into the part to be injected to finish injection;
preferably, the step of placing the stopper on the site to be injected, wherein the bottom end of the needle channel is aligned with the site to be injected comprises: the stopper contains that the one side of needle way is placed in eyeball top back to pupil direction, and the stopper bottom surface aligns with the edge that contains the one side relative of needle way and iris top edge.
The beneficial effect of this application: according to the injection device for ophthalmic injection, the distal end of the hollow needle body is provided with the thin part with a specific length through the design of the two-section type needle, so that the needle point of the thin part can be accurately positioned in the suprachoroidal space, and the needle point penetrates into the suprachoroidal space at a certain angle through the needle channel on the stopper, so that when liquid is pushed in, the liquid flow can form a small included angle with the choroidal space or even be approximately parallel to the choroidal space, and the risk of the liquid penetrating through the choroidal space is reduced; furthermore, the stopper adopts a specific width, so that the injection position can be conveniently and accurately shown; the utility model provides an injection device for ophthalmic injection simple structure, through the cooperation of stopper with the syringe, greatly reduced suprachoroidal space injection operation to doctor's experience's dependence, improve the accurate nature of injection operation, reduce the risk of penetrating the choroid.
Drawings
Fig. 1 is a schematic view of the structure of an ophthalmic syringe according to the present application.
Fig. 2 is a schematic view of a needle structure of an ophthalmic syringe according to the present application.
Fig. 3 is a schematic view of the hollow needle body and details of the needle of the ophthalmic injector of the present application.
Fig. 4 is a schematic structural view of the stopper for ophthalmic injection according to the present application.
Fig. 5 is a schematic view of the stopper of the present application placed on the top of the eyeball.
Fig. 6 is a schematic view of suprachoroidal space injection using the ophthalmic injection device of the present application.
Detailed Description
In order to more clearly illustrate the embodiments of the present application or the technical solutions in the prior art, the drawings needed to be used in the description of the embodiments or the prior art will be briefly described below, it is obvious that the drawings in the following description are only one embodiment of the present application, and other embodiments can be obtained by those skilled in the art according to the drawings.
Definition of
As used herein, the terms "a" and "an" and "the" and similar referents refer to the singular and the plural, unless otherwise indicated herein or clearly contradicted by context.
As used herein, the terms "about," "substantially," and "similar to" mean within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which error range may depend in part on the manner in which the value is measured or determined, or on the limitations of the measurement system.
The first aspect of the present application provides an injection device for ophthalmic injection, as shown in fig. 1 to 5, comprising a syringe and a stopper, wherein the syringe comprises a barrel 1 and a needle 2 which are detachably connected, the needle 2 comprises a pintle 21 and a hollow needle body 22, and the pintle 21 is used for connecting with the barrel 1; a thin part 23 is arranged at the far end of the hollow needle main body 22, the length of the thin part 23 is 0.6-2mm, the outer diameter of the thin part 23 is 0.25-0.35mm, and a needle point 24 is arranged at the far end of the thin part 23;
the stopper comprises a base 11 and a handheld part 12 arranged above the base 11, a needle channel 13 capable of embedding the hollow needle main body 22 is arranged on one side surface of the handheld part 12, and an included angle theta of 20-70 degrees is formed between the needle channel 13 and the axis of the stopper in the height direction, and is preferably 30-45 degrees; the needle channel 13 penetrates through the base 11;
the length of the needle channel 13 is less than or equal to the length of the hollow needle body 22, and when the hollow needle body 22 is embedded in the needle channel 13, the thin part 23 can be completely exposed from the bottom surface of the base.
The syringe needle of the application adopts a two-section type needle, namely, the syringe needle comprises a hollow needle main body 22 with a larger outer diameter and a thin part 23 with a smaller outer diameter, the thin part 23 can penetrate into a part to be injected, such as eyeball, under a smaller external force, and the hollow needle main body 22 with the larger outer diameter is kept outside the body, so that the injection depth is ensured not to exceed the length of the thin part; the length of the thin part 23 is 0.6-2mm, so that the injection depth is controlled to be in the suprachoroidal space, the length of the thin part is too small to penetrate through sclera and reach the suprachoroidal space, and the length of the thin part is too long to easily penetrate through the choroid, so that the penetration depth needs to be judged by the experience of an operator; the length of the thin portion 23 of the present application is set to 0.6-2mm, which allows the needle tip to be more easily positioned in the suprachoroidal space.
The thin part 23 of the application has the outer diameter of 0.25mm-0.35mm, and the outer diameter is too small, so that on one hand, the strength of the needle point is reduced, the sclera is not easy to puncture, and in addition, the too small outer diameter inevitably requires a smaller inner diameter, and the too small inner diameter is easy to cause blockage, thus being not beneficial to pushing out the injection; on the other hand, too small a diameter of the fine portion is not easy to process.
In some embodiments, the diameter of the thin portion 23 is 0.06 to 0.2mm.
In some embodiments, the detail 23 may be sized to the outside and inside diameters of a needle of International Standard 30G-34G.
In some embodiments, the needle tip 24 has a length of 0.25 to 0.35mm.
As used herein, the term "length of the tip" is understood to mean the length of the detail having the beveled portion, as is well known in the art, and in this application, the length of the detail encompasses the length of the tip; the length of the needle tip in the present application may be conventional in the art, and the inventors have found that when the needle tip length is 0.25-0.35mm, in combination with the angle of the needle track of the stopper of the present application, the direction of fluid egress during injection can be controlled to be approximately 0-60, preferably 0-30, to the choroid, thereby reducing the likelihood of fluid flow through the choroid.
In some embodiments, the hollow needle body 22 has an outer diameter of 0.8 to 2mm; in some embodiments, the hollow needle body 22 has an inner diameter of 0.5 to 1.6mm; in some embodiments, the hollow needle body 22 may employ the outer and inner diameter dimensions of a needle of the International Standard 14G-21G gauge.
The inventors have found that the length of the hollow needle body 22 is too long or too short, which is disadvantageous for the manufacturing process on the one hand and inconvenient for the injection operation on the other hand, and therefore, in some embodiments, the length of the hollow needle body 22 is 6-20mm.
In this application, the length of the hollow needle body is understood to be the length excluding the details.
In some embodiments, as shown in fig. 3, the thin portion 23 is connected to the hollow needle body 22 by a tapered connection 25; in some embodiments, the taper of the tapered connection is 2 to 3.5. The inventors have found that when the tapered connection is used to facilitate penetration of the detail into the eye, the needle mates with the surface of the eye.
In some embodiments, the hollow needle body 22 and the thin portion 23 can be made by integral molding, etc., and the material of the hollow needle body and the thin portion can be made of the conventional material of the needle in the art, such as stainless steel or other conventional material in the art, but the present invention is not limited thereto.
The pintle 21 may be of a conventional pintle structure, such as a plug-in type or a screw type, and is not limited herein. The attachment of the pintle to the hollow needle body is conventional in the art and may be accomplished by any means known in the art, and the application is not limited thereto. The length of the hollow needle body in this application is to be understood as the length of the part of the hollow needle body exposed outside the pintle.
In the present application, the syringe 1 may be a small-range syringe conventional in the art, preferably a syringe with a range of 1ml or less, and the present application is not limited thereto, and the syringe may be a syringe structure conventional in the art, for example, including an empty cylinder, a piston disposed in the empty cylinder, and a nipple disposed at an end of the empty cylinder, the nipple having an outer diameter or a thread matching with the pintle for connecting with the pintle, which is conventional in the art, and the present application is not limited thereto.
In some embodiments, the range of the syringe 1 is 100 to 1000 μ L; preferably 100-500. Mu.L; more preferably 100-200. Mu.L. Ophthalmic injections are usually small in injection amount, for example, not more than 200 μ L, so that the selection of a small-range syringe is advantageous in improving the accuracy of the injection amount.
In some embodiments, the barrel has an aspect ratio of 20 to 60; the inventor finds that the syringe has a larger length-diameter ratio, and the pushing path is longer and the liquid flow is smaller under the condition of injecting the same medicine quantity, so that the risk of the liquid flow penetrating through the choroid can be effectively reduced. The aspect ratio referred to in this application has a general meaning and is understood to be the ratio of the length of the needle cylinder to the internal diameter of the empty cylinder of the needle cylinder, said length of the needle cylinder being understood to be the length of the part of the needle cylinder provided with the graduations. The length of the syringe can adopt the length of a syringe of a conventional injector, in some embodiments, the length of the syringe is 5-8cm, and under the condition of not influencing operation, the length of the syringe is long, and the inner diameter of the syringe is small, so that the liquid pushing path is increased.
In some embodiments, the inside diameter of the barrel is 1-3mm.
In some embodiments, the syringe may be made of materials conventional in the art for syringe syringes, such as glass, high molecular weight polypropylene, etc., and the present application is not limited thereto.
In this application, the bottom surface of stopper base 11 is used for contacting with the eyeball, handheld portion 12 does the stopper provides a take the altitude to and convenient handheld. Any suitable shape may be selected by those skilled in the art to achieve this effect.
In some embodiments, the stopper has a bottom surface with a curvature that matches the surface of the ball. The utility model provides a stopper is used for ophthalmology to inject, consequently has less size, and its bottom surface can also have certain radian for the plane, can match with the radian of eyeball better.
In some embodiments, as shown in fig. 5, the base 11 of the stopper may be a rectangular parallelepiped, and the bottom width is also the stopper base width, which may be understood as the distance D between one surface of the needle track and the other surface opposite to the needle track. In some embodiments, the stopper base width D is 5-8mm; the stopper base is in this width range, can help the operator to inject the position and inject the suitable position of position limited in the eyeball, avoids injecting the position too back to effectively avoid the intensive region of optic nerve.
In some embodiments, the length L of the stopper base surface is 5-12mm. The length of the bottom surface can be understood as the distance between two side surfaces of the base adjacent to the surface provided with the needle track. The bottom surface of the limiter has a certain length, so that the limiter can be stabilized on the eyeball and is not easy to overturn.
In some embodiments, the height of the stopper is 1.5-3cm. The height of the stopper comprises the sum of the height of the base and the height of the handheld part. The stopper is too small in height, and when the stopper is fixed by fingers, the stopper is easily shielded, the needle insertion is inconvenient to observe, and the stopper is too large in height and easily overturns or wastes materials.
In some embodiments, as shown in fig. 4 or fig. 5, the base and the handle of the stopper may have distinct boundaries, for example, the base 11 is a rectangular parallelepiped with a thickness of 1-5mm, and the handle 12 is a rectangular parallelepiped with a length and a width respectively smaller than the length and the width of the base and a certain height; in some embodiments, the needle track is disposed on one side of the handle, the needle track extending from the interior of the base through the bottom surface; at this time, the side of the base provided with the needle channel can be understood as the side corresponding to the side of the handheld part provided with the needle channel; in some preferred embodiments, the base is flush with a surface of the handle on which the needle track is disposed, which facilitates observation of the needle insertion procedure by the operator.
In some embodiments, the base 11 has a thickness of 1-5mm.
In some embodiments, the base and the handle of the stop may also have no distinct boundaries, e.g., the entire stop is a cuboid; in some embodiments, the cuboid has a width of 5-8mm; the length is 5-12mm and the height is 1.5-3cm.
In some embodiments, the edges and corners of the stop are rounded to reduce damage that may occur if the stop touches the eyeball.
In some embodiments, the stopper may be made of any solid material that can be sterilized in the art, such as glass, high molecular polypropylene, stainless steel, etc., and preferably, the stopper is made of a transparent material, such as glass, high molecular polypropylene, etc., which is not prone to generate shadows during the injection operation, and is beneficial for the operator to observe the needle insertion.
In some embodiments, the width of the needle track 13 may be slightly larger than the outer diameter of the hollow needle body 22 to facilitate insertion of the needle into the needle track.
In the application, the needle inserting angle of the needle point of the syringe is controlled by designing the included angle theta between the needle channel and the axis of the height direction of the limiting device, so that a smaller angle is formed between liquid flow and the choroid, and the risk of the liquid flow penetrating through the choroid is reduced.
In some embodiments, the needle track 13 may have a length of 3-10mm.
A second aspect of the present application provides a needle for an ophthalmic injector, as shown in fig. 2 and 3, comprising a pintle 21 and a hollow needle body 22, said pintle 21 being adapted to be connected to said barrel; the far end of the hollow needle main body 22 is provided with a thin part 23, the length of the thin part 23 is 0.6-2mm, the outer diameter of the thin part 23 is 0.25-0.35mm, and the far end of the thin part 23 is provided with a needle point 24.
In some embodiments, the diameter of the thin portion 23 is 0.06 to 0.2mm.
In some embodiments, the needle tip 24 has a length of 0.25 to 0.35mm.
In some embodiments, the hollow needle body 22 has an outer diameter of 0.8 to 2mm; preferably, the hollow needle body 22 has an internal diameter of 0.5 to 1.6mm; preferably, the hollow needle body 22 has a length of 6-20mm.
In some embodiments, the thin portion and the hollow needle body are connected by a tapered connection.
In some embodiments, the taper of the tapered connection is 2 to 3.5.
In a third aspect, the present application provides a barrel for an ophthalmic injector having a length to diameter ratio of 20 to 60; preferably, the inner diameter of the needle cylinder is 1-3mm; preferably, the range of the needle cylinder is 100-500 muL; preferably 100-200. Mu.L.
A fourth aspect of the present application provides an ophthalmic injector, as shown in figure 1, comprising a needle 2 as provided in the second aspect of the present application and/or a barrel 1 as provided in the third aspect of the present application.
A fifth aspect of the present application provides a stopper for ophthalmic injection, as shown in fig. 4, which comprises a base 11 and a hand-held portion 12 disposed above the base 11, the stopper being provided with a needle channel 13 into which a needle of a syringe can be inserted on one side of the hand-held portion 12, the needle channel having an angle θ of 20 ° to 70 °, preferably 30 ° to 45 °, with an axis of a height direction of the stopper; the needle channel 13 penetrates through the base 11.
In some embodiments, the bottom surface of the base has a curvature that matches the surface of the ball.
In some embodiments, the height of the stopper is 1.5-3cm; preferably, the width of the bottom surface of the limiter is 5-8mm; preferably, the length of the bottom surface of the limiter is 5-12mm; preferably, the thickness of the base is 1-5mm; preferably, the needle track has a length of 3-10mm.
A sixth aspect of the present application provides a method of controlling the direction of egress of a syringe needle using an injection device of the first aspect of the present application, comprising:
injecting the injection into a needle cylinder, and connecting the needle cylinder with a needle head;
placing a hollow needle head main body of a needle head of the syringe in a needle channel of the stopper, wherein the open end of the needle point is upward;
the thin part of the syringe needle extends out of the bottom surface of the limiter along the needle path direction, and pushes the piston in the syringe to push out the injection in the direction which forms an included angle of 0-60 degrees with the bottom surface of the limiter.
A seventh aspect of the present application provides an injection device for ophthalmic injection of the first aspect of the present application, a needle of an ophthalmic injector of the second aspect of the present application, a barrel of an ophthalmic injector of the third aspect of the present application, or a use of an ophthalmic injector of the fourth aspect of the present application for ophthalmic injection; preferably, the ophthalmic injection is a suprachoroidal injection.
An eighth aspect of the present application provides a method for suprachoroidal space injection using the ophthalmic injection device of the first aspect of the present application, comprising:
injecting the injection into a needle cylinder, and connecting the needle cylinder with a needle head;
placing the stopper on a part to be injected, wherein the bottom end of the needle channel is aligned with a point to be injected;
placing a hollow needle head main body of a needle head of a syringe in a needle channel of the stopper, wherein the open end of the needle head is upward;
stretching the thin part of the injector out of the bottom surface of the limiter along the needle path direction, and penetrating the thin part into the part to be injected to finish injection;
preferably, the step of placing the stopper on the site to be injected, wherein the bottom end of the needle channel is aligned with the site to be injected comprises: the stopper contains that the one side of needle way is placed in eyeball top back to pupil direction, and the stopper bottom surface aligns with the edge that contains the one side relative of needle way and iris top edge.
A schematic diagram of suprachoroidal space injection using the ophthalmic injection device of the present application is shown in fig. 6.
The above description is only exemplary of the present application and should not be taken as limiting the present application, as any modification, equivalent replacement, or improvement made within the spirit and principle of the present application should be included in the protection scope of the present application.
Claims (12)
1. An injection device for suprachoroidal space injection comprising a syringe and a stopper, wherein said syringe comprises a barrel and a needle removably connected, said needle comprising a pintle for connection to said barrel and a hollow needle body; the hollow needle body adopts the outer diameter and the inner diameter of a needle with the specification of international universal standard 14G-21G; the distal end of the hollow needle head main body is provided with a thin part, the length of the thin part is 0.6-2mm, and the thin part adopts the outer diameter and the inner diameter of the needle head with the specification of international universal standard 30G-34G; the thin part is connected with the hollow needle head main body through a conical connecting part;
the far end of the thin part is provided with a needle point; the length of the needle point is 0.25-0.35mm;
the stopper comprises a base and a handheld part arranged above the base, a needle channel capable of embedding the hollow needle head main body is arranged on one side surface of the handheld part of the stopper, and an included angle of 20-70 degrees is formed between the needle channel and the axis of the stopper in the height direction; the needle channel penetrates through the base;
the length of the needle channel is smaller than or equal to that of the hollow needle head main body, and when the hollow needle head main body is embedded into the needle channel, the thin part can be completely exposed out of the bottom surface of the base.
2. An injection device as claimed in claim 1, wherein the needle track has an angle of 30 ° -45 ° to the axis of the stopper in the height direction.
3. An injection device according to claim 1, wherein the inside diameter of the detail is 0.06-0.2mm.
4. The injection device of claim 1, wherein the hollow needle body has an inner diameter of 0.5-1.6mm; the length of the hollow needle body is 6-20mm.
5. The injection device of claim 1 wherein the stopper has a bottom surface with a curvature to match the surface of the ball.
6. The injection device of claim 1, wherein the stopper has a height of 1.5-3cm; the width of the bottom surface of the limiter is 5-8mm; the length of the bottom surface of the limiting stopper is 5-12mm.
7. The injection device of claim 1, wherein the base has a thickness of 1-5mm.
8. The injection device of claim 1, wherein the syringe has a range of 100-1000 μ L.
9. The injection device of claim 1, wherein the syringe has a range of 100-500 μ L.
10. The injection device of claim 1, wherein the syringe has a range of 100-200 μ L.
11. The injection device of claim 1, wherein the barrel has an aspect ratio of 20-60.
12. The injection device of claim 1, wherein the inside diameter of the barrel is 1-3mm.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210851407.XA CN114983673B (en) | 2022-07-20 | 2022-07-20 | Injection device for ophthalmic injection and application thereof |
| CN202211364047.7A CN115887101A (en) | 2022-07-20 | 2022-07-20 | Injection device for ophthalmic injection and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210851407.XA CN114983673B (en) | 2022-07-20 | 2022-07-20 | Injection device for ophthalmic injection and application thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211364047.7A Division CN115887101A (en) | 2022-07-20 | 2022-07-20 | Injection device for ophthalmic injection and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114983673A CN114983673A (en) | 2022-09-02 |
| CN114983673B true CN114983673B (en) | 2022-11-15 |
Family
ID=83022109
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210851407.XA Active CN114983673B (en) | 2022-07-20 | 2022-07-20 | Injection device for ophthalmic injection and application thereof |
| CN202211364047.7A Pending CN115887101A (en) | 2022-07-20 | 2022-07-20 | Injection device for ophthalmic injection and application thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211364047.7A Pending CN115887101A (en) | 2022-07-20 | 2022-07-20 | Injection device for ophthalmic injection and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN114983673B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116035797B (en) * | 2023-03-06 | 2023-06-23 | 北京大学第三医院（北京大学第三临床医学院） | Anterior chamber of eye is device for puncture |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112891059A (en) * | 2021-03-24 | 2021-06-04 | 华中科技大学同济医学院附属同济医院 | Micropore drainage device for ophthalmic surgery and conveying system thereof |
| CN215020349U (en) * | 2021-04-29 | 2021-12-07 | 张星元 | Simple and easy tear duct of improvement type is visited and is put a tub ware |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013006752A1 (en) * | 2011-07-06 | 2013-01-10 | Bruce Becker | Retrobulbar syringe and methods of use |
| CN202960905U (en) * | 2012-11-13 | 2013-06-05 | 江苏省苏北人民医院 | Two-way push-injection exchanger |
| CN204909809U (en) * | 2015-08-14 | 2015-12-30 | 王晓刚 | Suction of glass body cavity and injection auxiliary device |
| CN105434103B (en) * | 2015-12-29 | 2017-07-07 | 北京大学人民医院 | A kind of miniature Glaucoma Drainage implanted device and system |
| CN206103065U (en) * | 2016-07-20 | 2017-04-19 | 刘齐兰 | Accurate syringe |
| CN208598918U (en) * | 2017-08-08 | 2019-03-15 | 温州市和平整形医院 | A kind of syringe of easily controllable injection |
| US10667944B2 (en) * | 2017-09-11 | 2020-06-02 | Samer Jaber Bashir | Ophthalmic intra ocular access tool |
| CN211356212U (en) * | 2019-12-12 | 2020-08-28 | 呼和浩特市第一医院 | Improved ophthalmic ball sub-fascia injection needle |
| CN213190528U (en) * | 2020-06-19 | 2021-05-14 | 深圳廷美奥生物技术有限公司 | Syringe with a needle |
| CN113476205B (en) * | 2021-08-16 | 2023-11-17 | 首都医科大学附属北京友谊医院 | Injection device for injecting medicine into vitreous cavity of eyeball with accurate positioning and quantitative injection |
| CN114129342A (en) * | 2021-12-24 | 2022-03-04 | 何宏 | Corneal stroma injection needle |
-
2022
- 2022-07-20 CN CN202210851407.XA patent/CN114983673B/en active Active
- 2022-07-20 CN CN202211364047.7A patent/CN115887101A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112891059A (en) * | 2021-03-24 | 2021-06-04 | 华中科技大学同济医学院附属同济医院 | Micropore drainage device for ophthalmic surgery and conveying system thereof |
| CN215020349U (en) * | 2021-04-29 | 2021-12-07 | 张星元 | Simple and easy tear duct of improvement type is visited and is put a tub ware |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114983673A (en) | 2022-09-02 |
| CN115887101A (en) | 2023-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11559428B2 (en) | Apparatus and methods for ocular injection | |
| EP3223760B1 (en) | Ocular therapeutics tool | |
| US7468065B2 (en) | Apparatus for delivery of ocular implants | |
| US20050203542A1 (en) | Apparatus for delivery of ocular implants with reduced incidence of ocular adverse events | |
| CN114983673B (en) | Injection device for ophthalmic injection and application thereof | |
| CN112603646A (en) | Suprachoroidal space syringe | |
| US20220401263A1 (en) | Eye surgery method using surgical cannulated instrument | |
| CN209154192U (en) | A kind of the operation special syringe and injection needle of ophthalmology vitreous chamber infusion art | |
| US20220370293A1 (en) | Combined biological sampling and injection assemblies and associated devices, systems, and methods | |
| CN211383190U (en) | Minimally invasive double-body touch quantitative laser tracing multipurpose puncture injection system | |
| WO2022237885A1 (en) | Medical penetration device and system | |
| US20160120694A1 (en) | Injection instrument and method | |
| CN110624159A (en) | Minimally invasive double-body touch quantitative laser tracing multipurpose puncture injection system | |
| US20150305932A1 (en) | Intraocular Injection Guide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: An injection device for ophthalmic injection and its application Effective date of registration: 20231030 Granted publication date: 20221115 Pledgee: Zhongguancun Beijing technology financing Company limited by guarantee Pledgor: Beijing Anlong biomedical Co.,Ltd. Registration number: Y2023990000521 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |